Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex. Patients 3 years of age or older with serial growth of subependymal giant-cell astrocytomas were eligible for this open-label study. The primary efficacy end point was the change in volume of subependymal giant-cell astrocytomas between baseline and 6 months.

Read the full abstract on PubMed →

Krueger, D. A., et al. (2010). Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1001671

@article{KRU2010,
  author       = {Krueger, D. A. and others},
  title        = {{Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis}},
  journal      = {New England Journal of Medicine},
  year         = {2010},
  doi          = {10.1056/NEJMoa1001671},
  note         = {PMID: 21047224},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record KRU2010) [Data set]. https://mtor-atlas.org/study/KRU2010/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_KRU2010,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record KRU2010},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/KRU2010/},
  doi          = {10.5281/zenodo.22059963}
}